Contact:
4008465777
-
About Us
News & Events
-
08-10
Tonghua Dongbao opens an online flagship store, tapping into Internet healthcare
Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter "Tonghua Dongbao" or "the Company") has doubled down on retail this year. Since March 2022, it has opened stores on mainstream e-commerce platform...
-
06-09
Tonghua Dongbao: Marketing application for GLP-1RA liraglutide injection accepted
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter "Tonghua Dongbao" or "the Company") received the notification of acceptance from the National Medical Products Administration (NMPA) on ...
-
05-19
Tonghua Dongbao: First subject enrolled in phase I clinical trial of BC Combo in Germany
In April 2022, Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") received the notice of approval from the Federal Institute for Drugs and Medical Devices (BfArM) in Germany...
-
05-10
Tonghua Dongbao: First subject enrolled in phase III clinical trial of BC Lispro in China
In October 2021, Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") received the notice of approval from the National Medical Products Administration (NMPA) for the clinical...
-
04-29
Tonghua Dongbao's Q1 earnings double with a net profit attributable to parent of RMB 831 million
On the evening of April 28, Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") released its quarterly report for Q1 2022. Specifically, the revenue hit RMB 887 million, up 7...
-
04-26
Tonghua Dongbao: First subject enrolled in phase I clinical trial of novel URAT1 inhibitor (THDBH130 Tablets) in China
In December 2021, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") r...